ELTX:

$2.82

+0.71%

Elicio Therapeutics Inc.

USD as of Aug 3, 2026 | NASDAQ - NASDAQ All Markets

Company Profile Russell 2000 Russell 3000

1-Year Price Evolution & Moving Averages

1-Year: -71.74%

Multi-timeframe price chart with technical indicators - United States dollar (USD)

Company Description

Company Profile

Elicio Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company engineers next-generation vaccines, immunomodulators, and adjuvants built on its proprietary lymph node–targeting Amphiphile (AMP) platform, designed to enhance the education, activation, and amplification of cancer-specific T cells. Its lead program, ELI-002, is an off-the-shelf, lymph node–targeted therapeutic vaccine candidate directed at the most common KRAS mutations implicated across a broad range of solid tumors, including pancreatic and colorectal cancers. By concentrating immune stimulation in lymph nodes, Elicio Therapeutics aims to generate potent and durable anti-tumor immune responses in high-prevalence, hard-to-treat cancers. The company maintains a diversified oncology pipeline based on the AMP platform, including AMP-powered cancer vaccines and AMP-DNA adjuvant technologies under clinical and preclinical development. Elicio Therapeutics is headquartered in Boston, Massachusetts, and operates within the global biotechnology and oncology research ecosystem.

United States Healthcare Biotechnology US Healthcare US Biotechnology

Risk & Valuation

as of Jul. 20, 2026

Beta	1.79
Trailing PE	5.75
Forward PE	-1.28

Stock Data

Open	$2.84
High	$2.89
Low	$2.75
Close	$2.82
Volume	38,812
Previous Close	$2.80
1-Day Change	+0.02
1-Year Change	-7.16
Average Daily Volume	503,253
52-Week High	$14.85
52-Week Low	$2.76

Disclaimer

All information and data available on Disfold is NOT FINANCIAL ADVICE. Invest at your own risk!

Past performance is not a guarantee of future performance. Patterns tend to repeat themselves, but they don't necessarily have to.

Furthermore, even though Disfold strives to provide the best and most accurate data, errors can occur in Disfold's systems, or in our data providers' systems.

Please conduct your own due diligence to verify insights.